Daclizumab (Zinbryta).
The objective of this systematic review is to examine the beneficial and harmful effects of Daclizumab (DAC) subcutaneously (SC) in the treatment of active relapsing-remitting multiple sclerosis (RRMS) in adult patients.
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK535191/ Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
[Ottawa, Ontario] :
Canadian Agency for Drugs and Technologies in Health,
2017
|
| Series: | Common drug review clinical review report.
|
| Subjects: |
